| Autor: |
Maurer GS; Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO 80309, USA., Clayton ZS; Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO 80309, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Future cardiology [Future Cardiol] 2023 Sep; Vol. 19 (11), pp. 547-566. Date of Electronic Publication: 2022 Nov 10. |
| DOI: |
10.2217/fca-2022-0086 |
| Abstrakt: |
Anthracyclines, chemotherapeutic agents used to treat common forms of cancer, increase cardiovascular (CV) complications, thereby necessitating research regarding interventions to improve the health of cancer survivors. Vascular dysfunction, which is induced by anthracycline chemotherapy, is an established antecedent to overt CV diseases. Potential treatment options for ameliorating vascular dysfunction have largely been understudied. Furthermore, patients treated with anthracyclines have impaired cognitive function and vascular dysfunction is an independent risk factor for the development of mild cognitive impairment. Here, we will focus on: anthracycline chemotherapy associated CV diseases risk; how targeting mechanisms underlying vascular dysfunction may be a means to improve both CV and cognitive health; and research gaps and potential future directions for the field of cardio-oncology. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
